

AMENDMENTS TO THE CLAIMS

1 – 27 (canceled).

28. (New) An apparatus for determining heparin-induced thrombocytopenia complex (HiT) comprising:

a first hemostasis testing cell to test a first portion of a whole blood sample taken from a HiT suspect patient to determine a first blood sample characteristic and to provide data indicative of the same;

a second hemostasis testing cell to test a second portion of the whole blood sample to determine a second blood sample characteristic and to provide data indicative of the same, the second portion having heparin added *in vitro* in a quantity sufficient to overwhelm platelet activation within the second portion; and

a processor coupled to the first testing cell and the second testing cell to receive the first blood sample characteristic data and the second blood sample characteristic data, respectively, to provide an indication of the presence of HiT based upon the first blood sample characteristic data and the second blood sample characteristic data.

29. (New) The apparatus of claim 28, wherein the first blood sample characteristic data are indicative of at least one of a clot strength measurement, a clot elasticity measurement, a clot rate of formation measurement and a clot rate of lysis measurement of the first whole blood sample.

30. (New) The apparatus of claim 28, wherein the second blood sample characteristic data are indicative of at least one of a clot strength measurement, a clot elasticity measurement, a clot rate of formation measurement and a clot rate of lysis measurement of the second whole blood sample.

31. (New) The apparatus of claim 28, the quantity comprises a quantity of heparin in excess of or equal to 5 microlitres (ul) of 1 Units / milliliter (U/ml).

32. (New) The apparatus of claim 28, the quantity comprises a quantity of heparin in excess of or equal to 5 microlitres (ul) of 3 Units / milliliter (U/ml).

33. (New) The apparatus of claim 28, the quantity comprises a quantity of heparin in excess of or equal to 5 microlitres (ul) of 30 Units / milliliter (U/ml).

34 (New) The apparatus of claim 28, the quantity comprises a quantity of heparin in the range of 5 microlitres (ul) of 1 Units / milliliter (U/ml) to 5 microlitres (ul) of 30 Units / milliliter (U/ml).

35. (New) The apparatus of claim 28, wherein the second blood sample characteristic represents a fibrin contribution to hemostasis.

36. (New) The apparatus of claim 28, wherein the first blood sample characteristic represents a contribution to hemostasis of activated platelets in the presence of HiT.

37. (New) The apparatus of claim 28, comprising a third hemostasis testing cell to test a third portion of the whole blood sample to determine a third blood sample characteristic and to provide data indicative of the same, the third portion having heparin added *in vitro* in another quantity, different than the quantity, sufficient to overwhelm platelet activation within the second portion; and

the processor being coupled to the third testing cell to receive the third blood sample characteristic data to provide an indication of the presence of HiT based upon the first blood sample characteristic data, the second blood sample characteristic data and the third blood sample characteristic data.

38. (New) The apparatus of claim 28, wherein each of the first portion and the second portion comprises a platelet rich plasma (PRP)-patient plasma mixture.

39. (New) The apparatus of claim 28, wherein each of the first portion and the second portion comprises patient whole blood.

40. (New) The apparatus of claim 28, wherein each of the first portion and the second portion comprises an activator.

41. (New) The apparatus of claim 28, wherein the first testing cell and the second testing cell each are testing cells of a multi-testing cell hemostasis testing machine.

42. (New) The apparatus of claim 28, wherein the first testing cell comprises a testing cell of a first hemostasis testing machine and the second testing cell comprises a testing cell of a second hemostasis testing machine.